All In Biotech

NDA 022134 · Abbvie

Lastacaft

Alcaftadine · Ophthalmic · Histamine-1 Receptor Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Aug 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jul 28, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

6

1 Phase 3, 0 recruiting

FAERS reports

907

133 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 10, 2022.

Us e temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LASTACAFT · ALCAFTADINE 0.25% · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Alcaftadine" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ocular hyperaemia299
  • eye irritation171
  • eye pain103
  • eye pruritus103
  • eye swelling84
  • drug ineffective65
  • hypersensitivity64
  • lacrimation increased57
  • eye discharge47
  • eyelid oedema42
  • erythema of eyelid39
  • conjunctivitis38

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201160
2012138
201366
2014163
201583
201649
201718
201819
201930
202019
202117
202221
2023104
202467
202537
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.